Diabetes, Vol 37, Issue 6 688-693, Copyright © 1988 by American Diabetes Association

ARTICLES

Are disturbances of sorbitol, phosphoinositide, and Na+-K+-ATPase regulation involved in pathogenesis of diabetic neuropathy?

DA Greene, SA Lattimer and AA Sima
Diabetes Research and Training Center, University of Michigan, Ann Arbor 48109.

Alterations in myo-inositol and phosphoinositide metabolism, induced by hyperglycemia and prevented by aldose reductase inhibitors, are implicated in impaired Na+-K+-ATPase regulation in peripheral nerve and other tissues prone to diabetic complications by an increasing range of scientific observations. However, the precise role of these related metabolic derangements in various stages of clinical complications is complex. For instance, it appears that these biochemical defects may play a role not only in the initiation of diabetic neuropathy but also in its later progression. Therefore, full appreciation of the potential pathogenetic role of altered phosphoinositide metabolism in diabetic complications requires detailed studies of both the earliest and the more mature stages of these disease processes.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. M. V. Valdivia, A. L. Dellon, M. E. Weinand, and C. T. Maloney Jr. Surgical Treatment of Peripheral Neuropathy: Outcomes from 100 Consecutive Decompressions J Am Podiatr Med Assoc, September 1, 2005; 95(5): 451 - 454. [Abstract] [Full Text] [PDF]

				A. V. Krishnan and M. C. Kiernan Altered nerve excitability properties in established diabetic neuropathy Brain, May 1, 2005; 128(5): 1178 - 1187. [Abstract] [Full Text] [PDF]

				M. J. Stevens, W. Zhang, F. Li, and A. A. F. Sima C-peptide corrects endoneurial blood flow but not oxidative stress in type 1 BB/Wor rats Am J Physiol Endocrinol Metab, September 1, 2004; 287(3): E497 - E505. [Abstract] [Full Text] [PDF]

				T. C. Coste, A. Gerbi, P. Vague, G. Pieroni, and D. Raccah Neuroprotective Effect of Docosahexaenoic Acid-Enriched Phospholipids in Experimental Diabetic Neuropathy Diabetes, October 1, 2003; 52(10): 2578 - 2585. [Abstract] [Full Text] [PDF]

				A. I. Vinik, R. E. Maser, B. D. Mitchell, and R. Freeman Diabetic Autonomic Neuropathy Diabetes Care, May 1, 2003; 26(5): 1553 - 1579. [Abstract] [Full Text] [PDF]

				M. A. Yorek, L. J. Coppey, J. S. Gellett, E. P. Davidson, X. Bing, D. D. Lund, and J. S. Dillon Effect of treatment of diabetic rats with dehydroepiandrosterone on vascular and neural function Am J Physiol Endocrinol Metab, November 1, 2002; 283(5): E1067 - E1075. [Abstract] [Full Text] [PDF]

				A. I. Vinik, T. Erbas, T. S. Park, K. B. Stansberry, J. A. Scanelli, and G. L. Pittenger Dermal Neurovascular Dysfunction in Type 2 Diabetes Diabetes Care, August 1, 2001; 24(8): 1468 - 1475. [Abstract] [Full Text] [PDF]

				D. M. Nathan The Pathophysiology of Diabetic Complications: How Much Does the Glucose Hypothesis Explain? Ann Intern Med, January 1, 1996; 124(1_Part_2): 86 - 89. [Abstract] [Full Text]

				R. Turner, C. Cull, and R. Holman United Kingdom Prospective Diabetes Study 17: A 9-Year Update of a Randomized, Controlled Trial on the Effect of Improved Metabolic Control on Complications in Non-Insulin-dependent Diabetes Mellitus Ann Intern Med, January 1, 1996; 124(1_Part_2): 136 - 145. [Abstract] [Full Text]

				B. Szwergold, F Kappler, and T. Brown Identification of fructose 3-phosphate in the lens of diabetic rats Science, January 26, 1990; 247(4941): 451 - 454. [Abstract] [PDF]